The HMBS Knockout SK-HEP-1 Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal population of SK-HEP-1 cells carrying a targeted disruption of the HMBS gene. As a heterogeneous knockout pool, this cell population provides a relevant model for studying loss-of-function effects without the constraints of monoclonal selection, enabling more representative functional analyses in a liver adenocarcinoma background. The product is designed for researchers investigating heme biosynthesis, porphyrin metabolism disorders, and related liver pathologies, offering a versatile tool for both mechanistic studies and therapeutic screening.
The SK-HEP-1 host cell line is an ascites-derived human liver adenocarcinoma cell line widely used as a model for hepatic sinusoidal endothelium and liver cancer research. SK-HEP-1 cells retain key characteristics of malignant hepatic cells and are well-suited for investigating tumor biology, drug response, and metabolic pathways intrinsic to the liver. Their endothelial-like features also make them valuable for studying liver-specific vascular interactions and the hepatic microenvironment. The CRISPR/Cas9-mediated gene disruption in this polyclonal knockout population preserves the natural heterogeneity of the parental line, allowing physiologically relevant assessments of HMBS function and its role in liver cancer cell behavior.
HMBS encodes hydroxymethylbilane synthase, a central enzyme in the heme biosynthesis pathway that catalyzes the condensation of four porphobilinogen molecules into hydroxymethylbilane. This step is critical for subsequent heme production and is tightly regulated by upstream factors such as GATA1 and NRF2, as well as by heme-mediated feedback inhibition. HMBS functions within a multi-enzyme complex that includes ALAS1, ALAD, UROS, and CPOX, and its activity directly influences the synthesis of uroporphyrinogen III, a downstream intermediate. Disruption of HMBS leads to the accumulation of porphobilinogen and delta-aminolevulinic acid, mimicking the metabolic derangements seen in acute intermittent porphyria and providing a mechanistic link between gene loss and disease pathology.
In the SK-HEP-1 hepatic adenocarcinoma context, HMBS knockout creates a powerful model for dissecting the interplay between heme metabolism, liver cancer biology, and porphyria-related phenotypes. The polyclonal knockout population allows the study of HMBS-dependent effects on cell proliferation, apoptosis, and metabolic reprogramming without clonal selection bias, making it particularly suitable for drug screening and pathway analysis. Researchers can exploit this model to explore how heme deficiency, porphyrin precursor accumulation, and compensatory regulatory mechanisms impact hepatic tumor cell fitness, redox balance, and response to therapeutic agents. The product thus bridges the gap between monogenic disease modeling and cancer-specific metabolic vulnerabilities.
This polyclonal knockout cell product facilitates a broad array of research applications, including functional validation of HMBS in heme biosynthesis, characterization of acute intermittent porphyria biomarkers via porphobilinogen accumulation assays, and transcriptomic profiling through RNA-seq to map pathway alterations. Additional uses include western blotting and RT-qPCR for confirming gene expression changes, heme quantification to assess metabolic flux, flow cytometry for measuring heme content, and apoptosis assays to evaluate cellular stress responses. These applications enable detailed mechanistic studies and high-throughput screening for potential therapeutics targeting heme pathway disorders or liver cancer. For additional technical details or to discuss custom applications, please contact Ascent Research.
